Author:
Liu Lunming,Shen Weifeng,Zhu Zhihui,Lin Jinxiong,Fang Qingxia,Ruan Yeping,Zhao Huajun
Funder
Zhejiang Provincial Natural Science Fund
National Natural Science Foundation of China
Zhejiang Public Welfare Program Application Research Project
National Pre-research Program of Zhejiang Chinese Medical University
Zhejiang Chinese Medical University Fund
Subject
Cell Biology,Molecular Biology,Biochemistry,Biophysics
Reference31 articles.
1. Biological determinants of endocrine resistance in breast cancer;Musgrove;Nat. Rev. Canc.,2009
2. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment;Howell;J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol.,2002
3. Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer;Kabos;Expet Opin. Pharmacother.,2010
4. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines;McClaine;Neoplasia, (New York, N.Y.),2010
5. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial;Osborne;J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol.,2002
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献